[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fluorescence-guided-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fluorescence-guided-surgery":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245",false,"NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma","ALL","18 Years",{"count":20,"type":21},341,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[27,28,29,30,31,32,33,34,35,36,37,38],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node","Sentinel Lymph Node Biopsy","Colon Neoplasms","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery","Indocyanine Green (ICG)",[40,33,41,42,43,44,45],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","RECRUITING","2025-11-17",{"date":49,"type":50},"2025-11-20","ACTUAL",{"date":52,"type":50},"2024-12-12",{"date":54,"type":21},"2032-12-12",{"name":56,"class":57},"Meander Medical Center","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":68,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":58},"100570559","augur-ai---indocyanine-green-fluorescence-angiography-representer-100570559","NCT06708819","AUGUR-AI - Indocyanine Green Fluorescence Angiography Representer","AUGUR-AI","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Aged 18 years or above.\n* Colorectal disease requiring segmental resection with anastomosis.\n* Participant has clinically acceptable laboratory results, including liver function tests.\n* In the Investigator's opinion, is able and willing to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n\nExclusion Criteria:\n\nThe participant may not enter the study if ANY of the following apply:\n\n* Participant who is pregnant, lactating or planning pregnancy during the course of the study.\n* Significant renal or hepatic impairment.\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Allergy to intravenous contrast agent or indocyanine green.\n* Concurrent use of anticonvulsants, bisulphite containing drugs, methadone and nitrofurantoin.",{"count":67,"type":21},300,"90 Days","OBSERVATIONAL","Surgery can effectively treat colorectal cancer, but it is a complex procedure with risks and complications. Surgeons often rely on cameras to visually guide their instruments during operations, especially in minimally invasive (\"keyhole\") and endoscopic procedures. The camera is connected to a computer and generates the internal scene onto a display screen, which the surgeon looks at throughout the procedure, helping them make informed decisions throughout the operation. Fluorescence-guided surgery uses a particular type of camera that can detect images in both normal light and in the near-infrared range. To work, it needs the administration of an agent called indocyanine green to a patient and then the camera can see if the agent is in the tissue of interest to the operation at the time of the surgery. In this way, decisions regarding blood supply (\"perfusion\") can be helped, especially related to safety in joining together portions of tissue after removal of disease. The equipment and agent are approved for use in this way and have very good safety profiles. Many international studies have already demonstrated that the use of fluorescence-guided surgery is associated with lower rates of leaks when disease bowel segments are removed, and the healthy ends are joined back together.\n\nPrevious work we have done has shown that sophisticated computing methods can learn to interpret the fluorescence patterns to a similar standard as a surgeon who is very experienced in fluorescence-guided surgery.\n\nIn this study, we aim to assess whether the computer system we have developed work in real-time, in theatre to provide a reliable interpretation of the fluorescence pattern, that would match how an expert would interpret the same pattern. The system's analysis will not impact on the operation; instead, video images will be recorded, processed and analysed by our computer system. The results of the interpretation will not be shown to the operating surgeon during the procedure to avoid any impact on decision-making.",[72,73,74,34,75,76,77],"Colorectal Surgery","Colorectal Resection","Anastomosis, Surgical","Indocyanine Green","Perfusion Imaging","Anastomotic Leaks",[33,75,79,80,81],"Artificial Intelligence","Bowel Transection","Anastomotic Leak","NOT_YET_RECRUITING","2024-11-26",{"date":85,"type":50},"2024-11-27",{"date":87,"type":21},"2025-01",{"date":89,"type":21},"2026-01",{"name":91,"class":57},"Mater Misericordiae University Hospital"]